Clinical Trial Search

Primary: Number of Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) as Assessed by CTCAE v. 3.0 Criteria Within the First 90 Days From…

Primary: Overall Survival Rate at 5 Years — 71; 72 Percentage of participants

Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants

Primary: Treatment Completion Rate — 37 Participants

Primary: Recurrence-free Survival (RFS) Rate at 3-years — 85.4; 88.5 percentage of participants — p=0.0927

Primary: Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression — NA; NA Months…

Primary: Overall Survival Rate

Primary: Tumor Response — 1; 7; 17; 34 participants

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator — 47.6; 47.5 Months — p=0.0004

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56

Primary: Tumor Response — 0; 4; 16; 7 participants

Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort

Primary: Overall Objective Response Rate (CR+PR) — 2; 5; 8 participants

Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants

Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants

Primary: Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation) — 32 participants

Primary: Percentage of Patients With Complete Tumor Regression Rate (TRG1) — 12.5; 50 percentage of participants

Primary: Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment — 0; 0; 2; 2 participants

Primary: Local Failure Free Survival — 9.4; 9.9 months

Primary: Change in Immunologic Markers Following Combination of Study Drug With Chemoradiation — 31.31; 140.33 ratio of cells per mm^2", "CD8+: FoxP3+

Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants

Primary: Number of Participants With Response — 0 Participants

Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants

Primary: Primary Event (Acute Hematologic or GI Toxicity) — 55; 46 Participants

Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83

Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants

Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants

Primary: Overall Response — 28 Participants

Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants